ABOUT OXLUMO™(lumasiran)

Target PH1 at the source of oxalate overproduction with OXLUMO1

OXLUMO is the first and only FDA-approved treatment for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.1-3

As an siRNA targeted specifically at the liver, OXLUMO harnesses the natural RNAi pathway to reduce hepatic oxalate production.1

RNA, ribonucleic acid; RNAi, RNA interference; siRNA, small interfering RNA.

A metabolic defect causes continuous oxalate overproduction in PH14,5

In primary hyperoxaluria type 1 (PH1), mutations in the AGXT gene impair function of a liver enzyme called AGT4,5:

  1. AGT function is impaired4,5
  2. Oxalate is continuously overproduced as a result5,6
  3. Continuous oxalate overproduction causes the symptoms of PH14

AGXT, alanine:glyoxylate aminotransferase; AGT, alanine:glyoxylate aminotransferase.

Image
Primary Hyperoxaluria Type 1 (PH1) Mechanism of Disease Diagram
Image
OXLUMO™ (lumasiran) Mechanism of Action (MOA)

OXLUMO reduces oxalate production1

OXLUMO decreases levels of glycolate oxidase (GO), an enzyme upstream of AGT. This reduces production of oxalate by the liver.1

Image

WANT TO SPEAK WITH AN OXLUMO REPRESENTATIVE?

Our representatives are available to provide detailed information about OXLUMO and how it may help your patients with PH1.

Let's Connect

Image
'

Want to see how OXLUMO is dosed?

Use the dosing guide to learn which dosing regimen is right for your patient.

Show Me the Dosing Regimens 

Download the Dosing Guide

Image
'

There’s more to learn about OXLUMO

When you sign up, we will keep you informed with updates and resources.

Sign Me Up

Image
Alnylam Assist® Logo

Here for patients treated with OXLUMO

Alnylam Assist® can help your patients get access to OXLUMO and provide support for patients throughout their treatment journey.

Let's Get Started

NEXT:

SEE EFFICACY AND SAFETY DATA FROM CLINICAL TRIALS WITH OXLUMO1

 EFFICACY & SAFETY

References: 1. OXLUMO (lumasiran) [Package Insert]. Cambridge, MA. Alnylam Pharmaceuticals, Inc. 2. Hoppe B. Nat Rev Nephrol. 2012;8(8):467-475. 3. Liebow A, Li X, Racie T, et al. J Am Soc Nephrol. 2017;28(2):494-503. 4. Milliner DS, Harris PC, Cogal AG, et al. https://www.ncbi.nlm.nih.gov/books/NBK1283/. Updated November 30, 2017. Accessed November 16, 2020. 5. Cochat P, Hulton SA, Acquaviva C, et al. Nephrol Dial Transplant. 2012;27(5):1729-1736. 6. Cochat P, Rumsby G. N Engl J Med. 2013;369(7):649-658.

IMPORTANT SAFETY INFORMATION

Adverse Reactions
The most common adverse reaction that occurred in patients treated with OXLUMO™ (lumasiran) was injection site reaction (38%). Symptoms included erythema, pain, pruritus, and swelling.

Pregnancy and Lactation
No data are available on the use of OXLUMO in pregnant women. No data are available on the presence of OXLUMO in human milk or its effects on breastfed infants or milk production. Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or the underlying maternal condition.

INDICATION

OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.

For additional information about OXLUMO, please see the full Prescribing Information.